NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies
DelveInsight's, 'Nonalcoholic Steatohepatitis Pipeline Insight, 2025' report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the NASH Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NASH Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the NASH Pipeline. Dive into DelveInsight's comprehensive report today! @ NASH Pipeline Outlook
Key Takeaways from the NASH Pipeline Report
In May 2025, Novo Nordisk A/S announced a study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.
In May 2025, Akero Therapeutics Inc. conducted a phase 2b study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH).
DelveInsight's NASH Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for NASH treatment.
The leading NASH Companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others.
Promising NASH Pipeline Therapies such as Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others.
Stay ahead with the most recent pipeline outlook for NASH. Get insights into clinical trials, emerging therapies, and leading companies with NASH@ NASH Treatment Drugs
NASH Emerging Drugs Profile
Lanifibranor: Inventiva Pharma
Lanifibranor, Inventiva's lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While other PPAR agonists target only one or two PPAR isoforms for activation. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH. Currently, the drug is in Phase III stage of its clinical trial for the treatment of NASH.
MSDC-0602K: Cirius Therapeutics
MSDC-0602K, a second-generation oral insulin sensitizer, is designed to selectively modulate the mitochondrial pyruvate carrier (MPC) while minimizing direct PPAR-gamma activation. The MPC mediates at the cellular level the effects of over nutrition, a major cause of Nonalcoholic fatty liver disease NAFLD/NASH and Type 2 diabetes. In preclinical studies, modulation of the MPC has been shown to improve insulin sensitivity, lipid metabolism, and inflammation. Currently the drug is in Phase III stage of Clinical trial for the treatment of NASH.
TERN-501 is a THR-β agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development. Agonism of THR-β increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. As a result, THR-β stimulation has the ability to reduce hepatic steatosis and improve serum lipid parameters including LDL cholesterol and triglycerides. In vivo NASH studies in a rodent model have demonstrated that low-doses of TERN-501 achieved complete resolution of steatosis and reductions in serum lipids, hepatic inflammation and fibrosis. TERN-501 has high liver distribution and is 23-fold more selective for THR-β than for THR-α activation in a cell free assay, thereby minimizing the risk of cardiotoxicity and other off-target effects associated with non-selective THR stimulation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of NASH.
HTD 1801: HighTide Biopharma
The company's lead drug candidate, HTD1801, is a first-in-class new molecular entity (ionic salt of two active moieties). It is a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while improving glycemic control and other cardiometabolic biomarkers in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2DM). Currently, it is in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH).
The NASH Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of NASH with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NASH Treatment.
NASH Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
NASH Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NASH market
Explore groundbreaking therapies and clinical trials in the NASH Pipeline. Access DelveInsight's detailed report now! @ New NASH Drugs
NASH Companies
Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others.
Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
NASH Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Unveil the future of NASH Treatment. Learn about new drugs, NASH Pipeline developments, and key companies with DelveInsight's expert analysis @ NASH Market Drivers and Barriers
Scope of the NASH Pipeline Report
Coverage- Global
NASH Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others.
NASH Pipeline Therapies- Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others.
NASH Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
NASH Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on NASH Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ NASH Companies, Key Products and Unmet Needs
Table of Contents
Introduction
Executive Summary
Nonalcoholic Steatohepatitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Nonalcoholic Steatohepatitis– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Lanifibranor: Inventiva Pharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
TERN-501: Terns Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
LY3849891: Eli Lilly and Company
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name : Company name
Drug profiles in the detailed report…..
Inactive Products
Nonalcoholic Steatohepatitis Key Companies
Nonalcoholic Steatohepatitis Key Products
Nonalcoholic Steatohepatitis- Unmet Needs
Nonalcoholic Steatohepatitis- Market Drivers and Barriers
Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion
Nonalcoholic Steatohepatitis Analyst Views
Nonalcoholic Steatohepatitis Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
18 minutes ago
- Globe and Mail
OXY Stock Outperforms Industry in Last Two Months: How to Play
Occidental Petroleum Corporation 's OXY shares have gained 18.8% in the last two months compared with the Zacks Oil and Gas-Integrated-United States industry's rally of 12.2%. The company operates in a very competitive industry, but Occidental's strong presence in the prolific Permian Basin works to its advantage. Occidental has outperformed some other operators in this space. In the same period, other operators in the same industry, like ConocoPhillips COP and Hess Corporation HES, have gained 9.6% and 9.8%, respectively. Price Performance (Two Months) Occidental is trading above its 50-day simple moving average (SMA), signaling a bullish trend. OXY's 50-Day SMA The 50-day SMA is a key indicator for traders and analysts to identify support and resistance levels. It is considered particularly important as it is the first marker of a stock's uptrend or downtrend. Should you consider adding OXY stock to your portfolio only based on positive price movements? Let's delve deeper and find out the factors that can help investors decide whether it is a good entry point to add OXY stock to their portfolio. Factors Acting as Tailwinds for Occidental Occidental continues to benefit from its strategic acquisitions, which have significantly boosted production volumes and top-line performance. Notably, the acquisition of CrownRock assets has enhanced output while reducing well operating costs. A key focus for Occidental is strengthening its balance sheet and lowering capital servicing expenses. In 2024, the company achieved its short-term debt reduction target of $4.5 billion and aims to further reduce outstanding debt by mid-2027 through free cash flow generation and proceeds from divesting non-core assets. The company's emphasis on developing its Permian Basin assets has been particularly fruitful. Occidental projects total production in 2025 to range between 1,390 and 1,440 thousand barrels of oil equivalent per day (Mboe/d), with the Permian accounting for approximately 760–786 Mboe/d. Under current economic and technical conditions, the company holds more than a decade of high-return drilling inventory in this region. To support its growth strategy, Occidental plans to invest between $3.5 billion and $3.7 billion in the Permian in 2025. In the first quarter alone, the company brought 125 wells online and targets drilling 515 to 565 wells by the end of the year. Its commanding regional presence is reflected in its control of 1.5 million acres in unconventional areas and 1.4 million acres in conventional zones. In addition to its robust U.S. operations, OXY also benefits from stable international performance, further strengthening its overall financial and operational outlook. Headwind for OXY Stock Occidental's operational performance is influenced by changes in demand and the volatility of both global and local commodity prices. The company remains vulnerable to fluctuations in the commodity markets, and as of Dec. 31, 2024, it had no active commodity hedging strategies in place. A significant decline in commodity prices from current levels could negatively affect Occidental's financial performance. OXY Stock's Earnings Surprise History The stable performance of the company allowed it to surpass earnings estimates in each of the last four reported quarters, the average earnings surprise being 24.34%. Hess Corporation, operating in the space, surpassed earnings estimates in each of the last four quarters, resulting in an average positive surprise of 9.58%. Occidental's Earnings Estimates are Going Down The Zacks Consensus Estimate for Occidental's 2025 and 2026 earnings per share has moved down 26.09% and 27.17%, respectively, in the past 60 days. ConocoPhillips' 2025 and 2026 earnings per share have gone down 18.93% and 25.40%, respectively, in the past 60 days. OXY's Shares Are Trading at a Premium Occidental's shares are currently expensive on a relative basis, with its current trailing 12-month Enterprise Value/Earnings before Interest Tax Depreciation and Amortization (EV/EBITDA TTM) being 5.11X compared with its industry average of 4.85X. ConocoPhillips and Hess Corporation are currently trading at EV/EBITDA TTM of 5.27X and 7.7X, respectively, a premium to the industry. Occidental's ROE Lower Than the Industry Occidental's return on equity ("ROE") is lower than the industry average in the trailing 12 months. ROE of OXY was 16.6% compared with the industry average of 16.89%. Summing Up Occidental's strength in its domestic and international operations and the positive impact of acquisitions are expected to support its performance. Yet, the company faces challenges from volatile commodity prices and returns that currently lag behind industry averages. Declining earnings estimates are also a concern. Despite the headwinds, it is advisable to keep this Zacks Rank #3 (Hold) stock in your portfolio, given its strong domestic operations and exposure to the prolific Permian Basin. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> ConocoPhillips (COP): Free Stock Analysis Report
Globe and Mail
33 minutes ago
- Globe and Mail
BlackRock Targets Raising $400B in Private Market Funds by 2030
BlackRock BLK is targeting $400 billion in private markets fundraising by 2030. In its investor presentation, the firm predicted that the private credit market could expand to $4.5 trillion in 2030 from $1.6 trillion last year. As the private credit market emerges as a lucrative sector in global finance, BlackRock has been strategizing to enhance its capabilities in the market by integrating investments, technology and data across the entire portfolio. In the presentation, the company mentioned that it aims to double its operating income and market capitalization by 2030. BLK targets its adjusted operating income to double to $15 billion by 2030 and its market cap to reach $280 billion. Showing further optimism, management mentioned that it has set its annual revenue target at more than $35 billion for 2030, implying a five-year compound annual growth rate of 10%. In 2024, the company earned revenues of $20 billion. Further, in these five years, the company expects organic base fee growth of 5% or more and its adjusted operating margin to be 45% or more. BlackRock's Foray Into the Private Markets Over the past year, BlackRock has committed nearly $28 billion to acquiring private-asset firms. In October 2024, it acquired Global Infrastructure Partners (GIP) for $12.5 billion to enhance its infrastructure offerings and origination capabilities. In December, it announced an agreement to acquire HPS Investment Partners for $12 billion in an all-equity transaction. BLK expects that once the HPS acquisition is complete, it will have about $220 billion of private credit client assets, adding to the more than $225 billion it had in private equity, infrastructure and real estate at the end of the first quarter of 2025. In May 2025, BlackRock acquired Preqin, a premier provider of private markets data, for $3.2 billion (£2.55 billion) in cash. The Preqin buyout represents a strategic expansion of BlackRock's Aladdin technology business into the private markets data segment. Preqin brings a substantial client base to BlackRock, including more than 4,000 relationships with general partners, limited partners and service providers. BlackRock has also collaborated with Partners Group to combine a varied pool of private assets into a single portfolio of alternatives for retail clients. Further, BLK is integrating private equity and credit investments into pre-built portfolios to cater to rising demand among individual investors. It designed model portfolios that combine publicly traded stocks and bonds alongside more sophisticated private equity and credit funds, with plans to add other alternatives over time. The company claims the offering to be the first of its kind in the asset management industry. Our View on BlackRock BLK's inorganic expansion strategy to boost its presence in alternatives and private equity assets, alongside its product diversification efforts, will likely aid top-line and assets under management growth. Moreover, the company's efforts to strengthen its iShares unit (offering more than 1,400 ETFs globally) and ETF operations (received approval for spot Bitcoin and ether ETFs), along with its increased focus on the active equity business, will aid financials. The combination of HPS Investment, Preqin and GIP data with BLK's alternative asset management platform, eFront, will drive solid revenue growth. BLK's Price Performance & Zacks Rank Over the past year, BLK shares have gained 28.5%, outperforming the industry 's 16.9% growth. Currently, BlackRock carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Like BLK, Other Firms Expanding in the Private Credit Market This February, JPMorgan JPM announced an additional $50 billion allocation toward direct lending, solidifying its presence in the credit market. The move, unveiled at its 30th annual Global Leveraged Finance Conference, signals the company's intent to become a dominant force in private credit. Since 2021, JPMorgan has deployed more than $10 billion across 100+ private credit transactions, leveraging its extensive client base and vast origination platform. The bank's partnerships with multiple co-lenders have further strengthened its position, bringing in an additional $15 billion in capital. According to Kevin Foley, global head of Capital Markets at JPM, the company's ability to integrate its origination platform with lender partners has significantly increased deal flow and lending capacity. In 2024, Citigroup C inked a deal with Apollo for its subsidiary and certain affiliates of Apollo to establish a revolutionary $25-billion private credit, direct lending program. The program will initially focus on North America, potentially expanding to additional geographies. Both Citigroup and Apollo expect the program to finance approximately $25 billion of debt opportunities over the next several years, including corporate and financial sponsor transactions. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> JPMorgan Chase & Co. (JPM): Free Stock Analysis Report Citigroup Inc. (C): Free Stock Analysis Report BlackRock (BLK): Free Stock Analysis Report
Globe and Mail
33 minutes ago
- Globe and Mail
Visa's Fintech Expansion: A New Era of Scalable Digital Payments?
Visa Inc. V focuses on sharpening its edge in the digital payments space through robust and growing fintech partnerships, acquisitions and platform building. It is redefining its role from a card network to a vital technology partner in the ever-changing payments landscape. The company saw impressive growth in payment volume during the second quarter of fiscal 2025, resulting from its partnerships with fintech companies and the increase in consumer spending on its app-based platforms. In fiscal 2023, Visa's payment volume rose 9% year over year on a constant-dollar basis, which grew 8% year over year in fiscal 2024, followed by an 8% increase in the second quarter of fiscal 2025. In the same quarter, processed transactions grew 9% year over year. Our model suggests a 9.9% year-over-year increase in processed transactions in fiscal 2025. Visa extended its partnership with TabaPay, which is serving over 6,500 fintechs and businesses. With Visa Direct, the company introduced push-to-account and wallet features alongside the existing push-to-card option. It also launched a new program, Visa Commercial Integrated Partners, designed to improve connectivity between fintechs and Visa Commercial products. Visa's proactive strategies reflect its active move to shape the new era of payments. As the demand for digital payment rises globally, the company's position as a flexible infrastructure partner might be its valuable long-term advantage. How Are Competitors Faring? Some of V's competitors in the fintech payments space are Mastercard Incorporated MA and PayPal Holdings, Inc. PYPL. Mastercard reported a 15% Y/Y increase in cross-border volumes in the first quarter of 2025. In the same quarter, its payment network net revenues grew 13% year over year. Mastercard projects adjusted net revenues to witness low-teens growth in 2025. PayPal Holdings' total payment volume increased 3% year over year in the first quarter of 2025. The company's payment transactions decreased 7% year over year in the same quarter. PayPal Holdings anticipates the transaction margin to be in the range of $15.2-$15.4 billion in 2025. Visa's Price Performance, Valuation & Estimates Shares of Visa have jumped 12.3% in the year-to-date period, outperforming the 8.5% growth of the industry. From a valuation standpoint, V trades at a forward price-to-earnings ratio of 30.1, above the industry average of 23.7. V carries a Value Score of D. The Zacks Consensus Estimate for Visa's fiscal 2025 earnings implies a 12.9% jump from the year-ago period. It witnessed 11 upward estimate revisions in the past 60 days against one downward movement. Visa stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Mastercard Incorporated (MA): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report This article originally published on Zacks Investment Research (
